Top Markets
#1 OVERTAKE OVERTAKE +228.34%
#2 Clearpool Clearpool +32.56%
#3 Rei Rei +31.55%
#4 PulseChain PulseChain +30.33%
#5 Playnance Playnance +28.14%
#6 Arcblock Arcblock +25.55%
#7 B3 (Base) B3 (Base) +25.04%
#8 龙虾 (Lobster) 龙虾 (Lobster) +22.59%
#9 Meteora Meteora +21.85%
#10 PondCoin PondCoin +18.44%
Coin of the day
OVERTAKE OVERTAKE
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Classifica tra le azioni #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Prezzo delle azioni
$62.26
Ultima sincronizzazione: 2026-09-22
Capitalizzazione di mercato
$127.18B
Variazione (1 giorno)
-0.78%
Variazione (1 anno)
38.63%
Paese
US
Scambia Bristol-Myers Squibb Company (BMY)

Categoria

Healthcare
Cronologia dei frazionamenti azionari per Bristol-Myers Squibb Company (BMY)
L’azione Bristol-Myers Squibb Company (simbolo: BMY) ha subito un totale di 6 frazionamenti.
L’ultimo frazionamento è avvenuto il Aug 07, 2001.
Una quota di BMY acquistata prima di May 31, 1977 equivale oggi a 33.621320960687 quote di BMY.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
2001-08-07 1000000:951777 x1.0506662800215 x33.621320960687
1999-03-01 2:1 x2 x32
1997-03-03 2:1 x2 x16
1987-06-10 2:1 x2 x8
1983-05-27 2:1 x2 x4
1977-05-31 2:1 x2 x2
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 4 x15
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 7 x432
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 0 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 2 x10000
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 7 x226
US